Thymalin Reconstitution Calculator

No. Thymalin is a registered pharmaceutical ("official medicinal product") in Russia and other former Soviet states, with decades of clinical use there. It holds no FDA approval and is not licensed as a medicine in most Western countries; outside Russia it is typically obtained as an unregulated research peptide. The published human evidence base is almost entirely Russian clinical data (observational).

Thymalin is a low-molecular-weight polypeptide complex extracted from calf thymus. Its active components are the short peptides KE, EW (L-Glu-L-Trp), and EDP, which bind double-stranded DNA and regulate gene expression. In vitro, Thymalin drives hematopoietic stem-cell differentiation, reducing stem-cell markers CD44 and CD117 by 2-3x while increasing the mature T-cell marker CD28 by 6.8x. In human mononuclear cells, Thymalin and the KE/EW dipeptides suppressed LPS-stimulated IL-1β, IL-6, and TNF-α by 1.4-6.0 fold (in-vitro). Net effect: T-cell immunity restoration with dampened inflammatory cytokine output, the basis for use in immunosenescence, viral infection, and post-chemotherapy immune depression.

The published human protocol is 10 mg intramuscularly once daily for 5 days, used in severe COVID-19 (observational). Body-weight-scaled veterinary data used 0.1 mg/kg IM twice, 72 hours apart, approximately 10 mg per injection for a 100 kg human,. Rat protocols used 0.01 mg/day IM for 7 days. Community protocols for immune restoration commonly replicate the hospital schedule: 10 mg IM daily for 5-10 days; 5-10 mg twice weekly also reported, repeated as quarterly-to-biannual courses (community protocol).

Intramuscular is the only route with published human data; every major human protocol used IM,,. Subcutaneous administration has no published human evidence but is common in peptide practice; the small peptide complex should absorb well SC, and SC avoids repeated muscle trauma (community protocol). Choose IM to replicate the clinical evidence exactly.

Clinical use is short and intermittent: 5 days for acute COVID-19, 7 days in rat regeneration models. In the 266-subject, 6-8 year geroprotective program, courses were repeated over the first 2-3 years, with one subgroup receiving annual combined courses for 6 years; mortality fell 2.0-2.1-fold versus control (observational). Thymalin and Thymogen are reported to have practically no side effects. Continuous daily dosing has not been studied; the evidence supports intermittent courses rather than chronic use.

There are no human reproductive-safety data; use in pregnancy or breastfeeding is unsupported without medical supervision. Preclinical signal: pregnant cows with genital mycoplasmosis treated with Thymalin (0.1 mg/kg IM, twice) plus antibiotic delivered calves with fully normalized protein metabolism and immunoglobulin profiles versus untreated infected controls (animal). This is veterinary-model safety evidence, not proof of safety in human pregnancy.

Thymogen is the synthetic single-dipeptide drug built from EW (L-Glu-L-Trp), one constituent isolated from Thymalin; the intact complex (KE + EW + EDP) is broader-spectrum,. In long-term human observation, mortality reduction favored Thymalin (2.0-2.1-fold) over Epithalamin (1.6-1.8-fold); the combination performed best (2.5-fold, and 4.1-fold in the 6-year annual-combination subgroup). Versus tocilizumab in severe COVID-19 (retrospective, non-randomized), Thymalin produced 2x lymphocyte/monocyte recovery and lowered D-dimer by 1.7x and fibrinogen by 1.2x. Case reports describe clinical recovery when Thymalin was added after tocilizumab failure (case report).

No published stability data exist. Lyophilized vials should be stored refrigerated (2-8°C) for long-term stability; brief ambient exposure during shipping is generally tolerated. After reconstitution with bacteriostatic water, refrigerate and use within ~30 days (community protocol).